BREAST CANCER

Sacituzumab govitecan shows a favorable safety profile in treating untreated triple-negative breast cancer, with manageable adverse effects compared to chemotherapy.

A groundbreaking blood test for early breast cancer detection shows exceptional accuracy, outperforming traditional mammography, especially in dense breast tissue.

FDA approves T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.

A new trial shows promising results for combining niraparib and dostarlimab in treating triple-negative breast cancer with BRCA mutations.

Premenopausal women with early breast cancer favor GnRHa therapy for fertility preservation during chemotherapy, with varying acceptance based on age and hormone receptor status.

A RAD51-based assessment identifies HER2-negative breast cancer patients likely to benefit from olaparib, enhancing treatment selection and outcomes.

Real acupuncture significantly enhances cognitive health in breast cancer survivors, outperforming usual care and showing promise over sham treatments.

New data from the TRIFOUR trial show that nadunolimab plus chemotherapy offers no significant survival benefit in metastatic triple-negative breast cancer.

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.

Long-term PALLAS study results reveal no survival advantage for palbociclib plus endocrine therapy over endocrine therapy alone in breast cancer patients.

New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use.

Elacestrant shows promising results in combination therapies for ER-positive, HER2-negative metastatic breast cancer, enhancing progression-free survival and maintaining safety.

A safety analysis reveals that sacituzumab govitecan and pembrolizumab combination therapy shows manageable side effects in treating metastatic triple-negative breast cancer.

A novel ctDNA assay identifies high-risk triple-negative breast cancer patients post-surgery, highlighting its potential as a crucial prognostic tool.

Alpelisib plus fulvestrant significantly improves progression-free survival in advanced breast cancer patients previously treated with CDK4/6 inhibitors.

Circulating tumor DNA analysis offers a minimally invasive method for detecting key genetic alterations in hormone receptor-positive breast cancer patients.

New research shows less invasive surgical options for breast cancer staging are as effective as traditional methods, enhancing patient quality of life.

New research reveals that preoperative breast MRI does not enhance outcomes for early-stage breast cancer patients, challenging its routine use in treatment plans.

New trial data reveals that combining preoperative radiation with pembrolizumab enhances immune response in high-risk, early-stage breast cancer patients.

Abemaciclib shows promise as a monotherapy for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitor failure, benefiting 33% of patients.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.